Dr. Mabel Yau
Pediatric Endocrinology (Pediatric Endocrinology Physician)
At a glance
- Medical school
- Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc) (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2008
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Rutgers R W Johnson Medical School (Cam/New Bruns/Pisc)
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Endocrinology Physician primary
NY license 256039 -
Pediatrics Physician
NY license 256039 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 4 companies reported 7 payments worth $3,976 in total to this clinician.
| Novo Nordisk Inc | $2,790 |
|---|---|
| Eton Pharmaceuticals, Inc. | $1,075 |
| BioMarin Pharmaceutical Inc. | $71.47 |
| AbbVie Inc. | $39.49 |
| Consulting Fee | $3,865 |
|---|---|
| Food and Beverage | $111 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Apr 17, 2025 | Consulting Fee Sogroya · Growth Hormone | $1,860 |
| Eton Pharmaceuticals, Inc. Apr 21, 2025 | Consulting Fee ALKINDI; KHINDIVI; INCRELEX · Endocrinology | $1,075 |
| Novo Nordisk Inc Apr 10, 2025 | Consulting Fee Sogroya · Growth Hormone | $465 |
| Novo Nordisk Inc Apr 18, 2025 | Consulting Fee Sogroya · Growth Hormone | $465 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $7,115 in research payments for these studies, mostly to the institutions running them.
- Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.